Novartis Ag通过其子公司Torino Merger Sub Inc已启动要约收购程序，计划收购Tourmaline Bio全部已发行普通股。根据收购条款，每股面值0.0001美元的普通股将以48美元现金价格进行收购，且不计利息。
此次要约收购针对Tourmaline Bio的所有流通在外普通股，收购方式为现金交易。
Novartis Ag通过其子公司Torino Merger Sub Inc已启动要约收购程序，计划收购Tourmaline Bio全部已发行普通股。根据收购条款，每股面值0.0001美元的普通股将以48美元现金价格进行收购，且不计利息。
此次要约收购针对Tourmaline Bio的所有流通在外普通股，收购方式为现金交易。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.